First Approved Human Age-Reversal Therapy
A regulatory authority (FDA or EMA) grants market approval for a therapy demonstrated to reverse at least one hallmark of aging in humans — epigenetic age, telomere length restoration, senescent cell clearance — in a properly powered clinical trial.
- Median year
- 2035
- P10 – P90 range
- 2030 – 2045
- Probability ever occurs
- 65%
- Last reviewed
- June 2026
A regulator approves the first therapy demonstrated to reverse — not just slow — a hallmark of aging. The event doesn't promise radical life extension, but it establishes the category: aging is now a modifiable medical target.
Progress in longevity science continues but no therapy achieves the standard of demonstrated reversal in a Phase 3 trial. The hallmarks of aging remain treatable only in narrow, organ-specific contexts.
Where things stand
In early 2026, the first partial epigenetic reprogramming therapy entered human Phase 1 clinical trials — a genuine milestone, marking the transition from animal-model research into the clinical pipeline. Phase 1 confirms human safety and dosing; it does not yet establish efficacy.
The scientific framework that makes this event trackable is the hallmarks of aging literature, which defines aging as a set of measurable, interconnected cellular processes — epigenetic drift, telomere shortening, senescent cell accumulation, and others. The definition above maps directly to this framework: a therapy qualifies if it reverses at least one of these hallmarks in a properly powered human trial.
Standard clinical timelines from a 2026 Phase 1 entry:
- Phase 1 (safety): 1–3 years
- Phase 2 (efficacy, small sample): 2–4 years
- Phase 3 (large-scale, pivotal): 3–5 years
- Regulatory review: 1–2 years
Under an optimistic path, earliest approval falls around 2030–2033. Under typical biotech attrition rates — most drugs that enter Phase 1 never reach approval — 2035 is more realistic. The 2045 bound accounts for the real possibility that early trials reveal safety concerns requiring redesign or that the reprogramming approach encounters limits not visible in animal models.
The p_ever of 0.65 reflects a genuine scientific uncertainty: partial reprogramming is biologically plausible and the pathway is now in human trials, but whether it will meet the strict efficacy bar required for regulatory approval — at a safety profile acceptable for broad use — is not guaranteed. Aging is a more complex target than most drugs address.